

SUPPORTIVE CARE

CHELSEA HOTEL, TORONTO, ON
ROOM: ROSSETTI A & B

APRIL 30, 2023, 8:00 AM – 12:00 PM

CO-CHAIRS : MICHAEL MCKENZIE & MARGOT BURNELL
SENIOR INVESTIGATOR: HARRIET RICHARDSON

Objectives for CME accreditation

1. To discuss the results of recent clinical trials in controlling symptoms of patients with cancer and the potential for translating this new knowledge
2. To discuss the role of psychosocial and other interventions such as cannabis to alleviate cancer symptoms, improve treatment-related outcomes, and improve overall patient experience
3. To identify opportunities to expand the use of palliative radiotherapy for the management of symptoms
4. To discuss clinical trials in the field of early palliative care and to consider opportunities for research to support caregivers of cancer patients.
5. To identify opportunities to integrate new measurement methodologies and/or correlative science in supportive care trials

8:00	Welcome	M.McKenzie/M. Burnell
8:05	Review of strategic priorities, progress to date and next steps	M. McKenzie/M. Burnell
8:20	Training the next generation of Clinical Trialists -CCTG New Investigator Cancer Trials Practicum	M. Yan
8:30	Active/Approved trials and Secondary Data Analyses CO21: CHALLENGE Trial (Exercise & Colon Cancer) SC26: Emotion and Symptom-focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia SC.28: The Seamless study: A randomized waitlist-controlled trial evaluation of a smartphone app-based mindfulness intervention for cancer survivors SC.29: A Phase III Trial Comparing Stereotactic Body Radiotherapy versus Conventional Palliative Radiotherapy in Patients with Painful Non-Spine Bone Metastases"	H. Richardson / C. Booth G. Rodin L. Carlson A. Sahgal
8:50	Closed Trials HE1: RT and Symptomatic Liver Ca BL.13F: Electronic 'Real-Time' Patient Self-Reporting of Immunotherapy Symptomatic Adverse Events using the SYMPTOM-IQ Tool on the uMotif Mobile Health Application (APP): A Prospective Feasibility Sub-	L. Dawson D. Howell



	SC.27: Living with Cancer in the Time of COVID-19	H. Richardson / L. Carlson
	TRIAL PROPOSALS	
9:20	-TEMPO SMART Trial -I CAN Manage Trial -Psilocybin Assisted Therapy for demoralization in advanced cancer	S. Lambert D. Howell L. Carlson
10:00	Break	
10:15	Special Topics	
	<ul style="list-style-type: none"> • Immunotoxicity Research Agenda (30 min) <ul style="list-style-type: none"> -Options for Remote Monitoring of Toxicities - Microbiome and immunotherapy toxicity • Standardized Reporting Outcomes (30 min) <ul style="list-style-type: none"> -New Symptom Measurement platforms (PROMIS, e-PROs) -Methodological designs for early trials, the use of PRO's in early trials • Updates on (15 min): <ul style="list-style-type: none"> -Cannabis research agenda • Geriatric Research Agenda (10 min) • NCI Working Group (10 min) • CCTG EDIIA Working Groups (10 min) 	D. Howell R. Pero D. Howell C. Yap L. Balneaves/C. deAngelis T. Hsu D. Howell & H. Horlock M. McKenzie/ A. Johnson
12:00	Wrap-Up and Meeting Adjourned	M.McKenzie/M. Burnell

